文献速递产科母胎医学

早孕期竞争风险模型预测小于胎龄儿

Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-12-09

模型对早产、严重SGA及合并子痫前期的预测效果更好,在10%假阳性率下,对≥37周、<37周和<32周分娩的SGA(出生体重<第10百分位)分别预测34.3%、48.6%和59.1%的病例。

要点

  • 竞争风险模型可个性化预测不同孕周和严重程度的SGA。
  • 子宫动脉搏动指数是早产SGA的最佳生物物理预测指标。
  • 胎盘生长因子是早产SGA的最佳生化标志物。

核心结论

  • 基于早孕期母体因素及生物物理和生化标志物的竞争风险模型可连续二维预测SGA,为个性化产前管理提供基础。

主要发现

  • 对早产SGA的最佳生物物理预测指标为子宫动脉搏动指数,最佳生化标志物为胎盘生长因子。
  • 随着早产程度增加、胎儿更小、合并子痫前期及标志物数量增多,SGA预测效果持续改善。
  • 母体因素联合所有标志物在10%假阳性率下,对出生体重<第10百分位且分娩≥37周、<37周和<32周的SGA分别预测34.3%、48.6%和59.1%的病例。
  • 对出生体重<第3百分位者,相应预测率分别为39.9%、53.2%和64.4%;合并子痫前期时分别为46.3%、66.8%和80.4%。
  • 新模型校准良好。

临床怎么用

  • 可在早孕期利用母体因素和标志物组合,针对不同SGA严重程度和分娩孕周进行个性化风险预测。
  • 模型支持用户自定义的SGA切点和孕周切点,便于临床灵活应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a new competing-risks model for the prediction of a small-for-gestational-age (SGA) neonate, based on maternal factors and biophysical and biochemical markers at 11-13 weeks' gestation. METHODS: This was a prospective observational study in 60 875 women with singleton pregnancy undergoing routine ultrasound examination at 11 + 0 to 13 + 6 weeks' gestation. All pregnancies had pregnancy-associated plasma protein-A and placental growth factor (PlGF) measurements, 59 001 had uterine artery pulsatility index (UtA-PI) measurements and 58 479 had mean arterial pressure measurements; 57 131 cases had complete data for all biomarkers. We used a previously developed competing-risks model for the joint distribution of gestational age (GA) at delivery and birth-weight Z-score, according to maternal demographic characteristics and medical history. The likelihoods of the biophysical markers were developed by fitting folded-plane regression models, a technique that has already been used in previous studies for the likelihoods of biochemical markers. The next step was to modify the prior distribution by the likelihood, according to Bayes' theorem, to obtain individualized distributions for GA at delivery and birth-weight Z-score. We used the 57 131 cases with complete data to assess the discrimination and calibration of the model for predicting SGA with, without or independently of pre-eclampsia, by different combinations of maternal factors and biomarkers. RESULTS: The distribution of biomarkers, conditional to both GA at delivery and birth-weight Z-score, was best described by folded-plane regression models. These continuous two-dimensional likelihoods update the joint distribution of birth-weight Z-score and GA at delivery that has resulted from a competing-risks approach; this method allows application of user-defined cut-offs. The best biophysical predictor of preterm SGA was UtA-PI and the best biochemical marker was PlGF. The prediction of SGA was consistently better for increasing degree of prematurity, greater severity of smallness, coexistence of PE and increasing number of biomarkers. The combination of maternal factors with all biomarkers predicted 34.3%, 48.6% and 59.1% of all cases of a SGA neonate with birth weight < 10th percentile delivered at ≥ 37, < 37 and < 32 weeks' gestation, at a 10% false-positive rate. The respective values for birth weight < 3rd percentile were 39.9%, 53.2% and 64.4%, and for birth weight < 3rd percentile with pre-eclampsia they were 46.3%, 66.8% and 80.4%. The new model was well calibrated. CONCLUSIONS: This study has presented a single continuous two-dimensional model for prediction of SGA for any desired cut-offs of smallness and GA at delivery, laying the ground for a personalized antenatal plan for predicting and managing SGA, in the milieu of a new inverted pyramid of prenatal care. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Papastefanou I, Wright D, Syngelaki A, et al. Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2020. PMID: 33094535. doi:10.1002/uog.23523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。